Dr.Konry has established a new biomedical research thrust focused on dynamic analysis of cellular functional phenotypes via lab-on-a-chip single cell and tissue-chip technologies to dissect the variability in immune and cancer cell responses to therapies. She was nominated as Phase 1 Finalist of Follow That Cell Challenge/NIH for
her work in single-cell proteomics which was also spotlighted in GEN magazine. She received Biosciences Immunology Research award from Becton Dickinson (BD) and Schumacher Faculty Award/NEU. Furthermore, her work was nominated for SLAS Innovation Award recognizing the novelty and integrated use of her work.
She was also appointed to the Women in Microfluidics & BioMEMS List and nominated for prestigious AllenDistinguished Investigator (ADI) award. Dr.Konry’s research has been funded by NIH (R01, R33, U54 and R21), NSF/CBET, foundations and industrial grants. Her collaborative work was selected for funding three times by
DFCI /NEU Joint Program in Cancer Drug Development and was awarded three times with Tier 1/NEU. Her patented engineering Lab on a Chip approach allowed her to establish collaboration with MGH Diabetes Center and was awarded by JDRF with a grant to integrate the device developed by Dr.Konry into clinical settings. Her
tissue-chip project was awarded with Sandia National Laboratories Collaborative grant.
Furthermore, Dr.Konry generated several funded collaborations with leading immunotherapeutic and biotech companies. Recently her lab developed a novel point of care technology (issued IP) for COVID-19 diagnostics and DNA/RNA analysis, awarded with CTSI Tufts, Radx phase 0 and Radx Next/CIMIT grants (Radx NIH program). In 2022 Dr.Konry established collaborations with Sanofi and Takeda Inc (funding $120,000) and Abcuro Inc (fee for service agreement /NEU and materials to support this project). She was awarded in 2022 with AHA grant (PD/PI $750,000).